All In Biotech

Drug Trial Radar · NCT07868237

A Phase I Study to Investigate KH-001 in Healthy Males

A Phase I, Randomised, Double-blind, Placebo-controlled First in Human Study to Assess the Safety and Pharmacokinetics of KH-001 Besylate in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Nov 14, 2023

Primary completion

Aug 28, 2025

Study completion Aug 28, 2025

Sponsor

Lead sponsor
Kadence BioIndustry
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a Phase I, first-in-human study of KH-001 besylate in healthy male participants, conducted to investigate the safety, tolerability and pharmacokinetics (PK) of the study drug. The study was conducted in three parts: a single ascending dose (SAD) part, a multiple ascending dose (MAD) part, and a Formulation Effect part evaluating an orodispersible tablet (ODT) formulation. The study also evaluated the effect of KH-001 besylate on suicidality risk and mood. KH-001 besylate is being developed as an on-demand oral treatment for premature ejaculation.

Conditions

  • Healthy Male Volunteers

Interventions

  • KH-001 besylateDrug

    Associated arm(s): 1 and 3

  • KH-001 besylate placeboDrug

    Associated arm(s): Arm 2 (Placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through the final follow-up visit (up to Day 12)
  2. Number of Participants With Clinically Significant Abnormal Clinical Laboratory ValuesTime frame: From screening through the final follow-up visit (up to Day 12)
  3. Number of Participants With Clinically Significant Abnormal Vital SignsTime frame: From screening through the final follow-up visit (up to Day 12)
  4. Number of Participants With Clinically Significant Abnormal 12-Lead ECG FindingsTime frame: From screening through the final follow-up visit (up to Day 12)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Simbec-Orion Clinical Pharmacology Unit

    Merthyr Tydfil, South Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.